Recently, our company’s holding subsidiary, Huonland, has obtained the “Drug Registration Approval” for the chemical drug “Sodium Hyaluronate Eye Drops,” approved and issued by the National Medical Products Administration. The approval number is Guoyao Zhunzi H20193204, and the specification is 0.3% (0.8 ml: 2.4 mg). This marks another new ophthalmic product added to Huonland’s portfolio, following its earlier approval of Brimonidine Tartrate Eye Drops.

　　Sodium hyaluronate eye drops are primarily used to treat endogenous conditions such as Sjögren’s syndrome, Stevens-Johnson syndrome, and dry eye syndrome, as well as corneal and conjunctival epithelial damage caused by exogenous factors including post-surgical complications, drug-induced effects, trauma, and contact lens wear. The product that has now received approval is a preservative-free, daily disposable eye drop formulation with the same 0.3% concentration as the product manufactured by Santen Pharmaceutical Co., Ltd. in Japan. Its fill volume is 0.4 ml, whereas our company’s product has a fill volume of 0.8 ml, making it more suitable for clinical use. Most of the sodium hyaluronate eye drops currently available on the market are multi-dose products at a concentration of 0.1%. Our company’s product boasts a higher concentration, offering rapid onset of action and superior therapeutic efficacy, which makes it highly favored by both clinicians and patients. Moreover, our product is manufactured using an advanced, integrated “blow-fill-seal” (BFS) sterile automated production line, ensuring maximum quality assurance.

　　With the widespread use of computer terminals and mobile phones, as well as factors such as atmospheric pollution, eye fatigue syndromes—most notably dry eye syndrome—are on the rise. According to incomplete statistics, the global prevalence of dry eye syndrome ranges from 7% to 34%, while in China, the prevalence is between 21% and 30%. If left unprevented and untreated, dry eye syndrome can lead to damage to the ocular surface, resulting in reduced vision and compromising the health of affected individuals.

　　Artificial tears are commonly used to treat dry eye syndrome, and sodium hyaluronate eye drops represent the most effective and safest product among artificial tears for this condition. According to data from the China Pharmaceutical Information Center’s PDB database, in 2016, nationwide sales of sodium hyaluronate eye drops reached 939 million yuan, with a year-on-year growth rate of 20.09%. From 2011 to 2016, sales grew steadily each year at an average rate of 20% to 25%, significantly higher than the average growth rate of other pharmaceutical products. Currently, the market size for this drug is approximately 5 billion yuan. In particular, there is strong market demand—and promising prospects—for sodium hyaluronate eye drops that do not contain preservatives.

　　Huonland is a newly established pharmaceutical manufacturer specializing in ophthalmic drugs. Sodium Hyaluronate Eye Drops are the company’s first single-dose product developed through its own R&D efforts. The company is actively preparing for GMP certification of the production line for this product, aiming to bring it to market as soon as possible and provide high-quality medications to a wide range of patients. Currently, other new products that have entered the review stage include Balanced Saline Solution and Olopatadine Hydrochloride Eye Drops. Once these products are approved, the company will have established a robust product portfolio, laying a solid foundation for its long-term, stable development and generating significant economic and social benefits.